Clinical Trial Update: A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of MK-8776 (SCH 900776) with and without gemcitabine in solid tumors or lymphoma completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Neoplasms
• Non-hodgkin Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• MK-8776 (SCH 900776) (MK-8776)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hodgkin Disease, Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED | Results posted: 2017-06-20